Dr Shakiba Kaveh is CEO of Mitra Bio which is building a non-invasive skin multi-omics platform to unravel skin health and delay ageing. The global anti-aging market was worth $60 billion in 2020. However for the past 50 years, skincare and anti-ageing products have targeted the signs of ageing - such as eliminating wrinkles - rather than stopping cellular ageing itself. Mitra bio has raised investment from Illumina Accelerator, Entrepreneur First, First-in Ventures and Cambridge & Peterborough Combined Authority. It is developing a longevity tool for skincare companies based on DNA methylation signatures which are associated with skin quality and age. This will differentiate skin conditions (old vs young; UV-damaged vs healthy) and lead to skincare personalisation and development of novel anti-ageing formulations. Shakiba has a PhD in Materials Science from Cambridge, over five years' experience in management consultancy, and is a former scientist at L'Oréal.